Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AFLIBERCEPT AVE0005 Clear all
Active, not recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

NCT02462889
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Intravitreal aflibercept injection, Placebo
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02401945
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 23, 2026, 5:16 PM EDT
Terminated Phase 2 Interventional Results available

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

NCT02418754
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN2176-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

NCT00284141
View directory record Official record
Conditions
Pulmonary Diseases, Neoplasms, Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 23, 2026, 5:16 PM EDT
Terminated Phase 2 Interventional Results available

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
Interventions
GEM103, Aflibercept, Sham
Biological · Drug
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Campbell, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501
View directory record Official record
Conditions
Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
Interventions
docetaxel, ziv-aflibercept, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

NCT01661972
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Capecitabine and aflibercept
Drug
Lead sponsor
John Strickler, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 23, 2026, 5:16 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

NCT02976012
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept, Endolaserless Vitrectomy
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

NCT02732899
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Sirolimus, EYLEA
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
50 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

NCT04964089
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
65
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 23, 2026, 5:16 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

NCT04989699
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI/Sham, Aflibercept/Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

NCT04527107
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

NCT00320814
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
VEGF Trap-Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 23, 2026, 5:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

NCT03297684
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept Injection [Eylea]
Drug
Lead sponsor
Advanced Eye Research Associates
Industry
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
South Dartmouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

NCT01495221
View directory record Official record
Conditions
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Interventions
Alfilbercept
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 23, 2026, 5:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 5:16 PM EDT
Terminated Phase 3 Interventional Results available

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

NCT00574275
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Sep 23, 2026, 5:16 PM EDT
Withdrawn Phase 4 Interventional

Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

NCT01495208
View directory record Official record
Conditions
Fibrovascular Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 23, 2026, 5:16 PM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 23, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

NCT04270747
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
ABP 938, Aflibercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 23, 2026, 5:16 PM EDT